Crinetics Pharmaceuticals will present six abstracts at ENDO 2026, showcasing data on PALSONIFY™ (paltusotine) for acromegaly and atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. The presentations include long-term safety and efficacy results reinforcing PALSONIFY's role as a best-in-class oral treatment for acromegaly, recently approved in the US and EU. Data on atumelnant demonstrate its potential to reduce glucocorticoid doses and control hormone excess in difficult endocrine diseases. These updates underscore Crinetics' commitment to advancing therapies for challenging endocrine conditions with ongoing Phase 3 trials and further clinical development.
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
